A critique of a 2022 university systematic review of e-cigarettes and health outcomes
Source material dated April 2022 · Research evidence
Overview
In April 2022, a team from the Australian National University released a long systematic review of global evidence on e-cigarettes and health outcomes, prepared for the federal health department. The source was a same-day opinion piece that disagreed with the review. It argued the review set out potential harms of vaping without weighing them against the harms of smoking, and that it understated vaping as a quitting aid. The source expected the review to be used to support tighter government controls.
Main objections
According to the source, the review listed many risks without putting numbers on them, and some of those risks were small. It also disputed the review's treatment of several topics:
- The source rejected the idea that vaping by non-smokers leads them to smoke, preferring an explanation based on shared risk-taking tendencies among young people.
- It said the review doubted vaping as a quitting aid, whereas the source pointed to randomised trials, population studies and falling smoking rates in countries with wider access.
- It argued the review linked nicotine vaping to the lung illness EVALI even though many patients who denied using cannabis vapes were later found to have used them.
- It described concerns about explosions, poisonings, seizures and nicotine toxicity as exaggerated or unsupported.
- It disputed the claim that dual use of cigarettes and vapes is the dominant pattern, citing survey figures from the United States, the United Kingdom and Australia, and arguing that dual use tends to fall over time.
Cancer, dependence and overall balance
The source said the review found no evidence on cancer risk, while the source cited studies it described as assessing that risk as a small fraction of the risk from smoking. It also cited studies it said showed vaping is less addictive than smoking. On the overall balance, the source noted that the review found insufficient evidence that benefits outweigh harms for current smokers. It argued this ignored modelling studies, one of which estimated millions of premature deaths averted if most United States smokers switched. The source accepted that more information was needed.
Context and limits
The piece is an advocacy response written on the day of publication, so it could not reflect a full reading of the review's 361 pages, and the figures are the source's own. The modelling estimates depend on assumptions about how many smokers would switch. The review itself and later commentary may have taken different positions.
Based on a 2022 opinion article.
Related summaries
- A 2025 randomised trial of vaping versus nicotine replacement among disadvantaged smokers
- A 2024 British medical college report on e-cigarettes and harm reduction
- Tobacco industry transformation and nicotine: a 2023 rebuttal
- Four researchers' 2023 evidence review of nicotine vaping for lawmakers